{
  "docId": "019de073-cc15-73cb-b985-dc28972c4284",
  "docSlug": "df7f4367d54f16f4cdacd02ff486e30b",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 27,
  "pageCount": 31,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide highlights a $2.75M upfront payment and the strategic synergy between Matinas' LNC platform and BioNTech's mRNA expertise.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/27",
  "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284",
  "deckJsonHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284.json",
  "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.3,
        "x": 0.65,
        "y": 0.15
      },
      "kind": "image",
      "text": "Hexagonal diagram showing partnership between Matinas and BioNTech",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b226aa61-0c39-48cc-a0ab-e3b0c195eb0a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.5,
        "x": 0.1,
        "y": 0.7
      },
      "kind": "list",
      "text": "Oral bioavailability and enhanced stability\nNon-immunogenic transfection\nAble to elicit strong humoral and cellular immunity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75f669e7-b0c0-4b1b-a322-eca5050acc57",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.55,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "list",
      "text": "Focused on mRNA and certain other nucleic acids\n$2.75 million upfront exclusive access fee plus research funding\nOngoing license agreement negotiations\nBioNTech's mRNA vaccine development expertise combined with Matinas' LNC delivery platform\nBuilds on Matinas' extensive prior preclinical in-vitro vaccine work with LNC formulations of proteins, peptides and DNA plasmids",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8781b0fd-dc0e-40b4-b0ac-16cf69f7b243",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "LNC-mRNA: Exclusive Research Collaboration with BioNTech",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f32960d0-63e4-450c-b75c-bd764ea72a26",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}